Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that it and longtime partner MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) have signed a new license agreement granting MSD the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric™ and EFECT™ platforms.